Uffaf, currently in her third year of pursuing a Ph.D. at the Texas A&M University Institute of Biosciences and Technology in Houston, Texas, is dedicated to advancing the field of rare and aging disorders. Her thesis research specifically revolves around the development of an innovative nanozyme drug therapy for treating mitochondrial diseases. Prior to her doctoral studies, Uffaf garnered valuable experience in the biotech industry, serving as a regulatory and quality officer at a prominent genetic sequencing company for nearly four years. During this time, she accumulated extensive expertise collaborating with regulatory bodies such as the FDA, CAP, CLIA, and various other agencies. Beyond her academic and professional pursuits, Uffaf finds joy in spending quality time with her family and friends. She is also passionate about contributing to her community through volunteer work.